Company and Stock Identity

How Therapixel Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
Therapixel holds five mammography clearances in this site's FDA records, the newest dated 26 June 2026, but its press page carries outside coverage rather than dated company releases. Ask the company in writing which clearance covers 2D mammography, which covers 3D, and which reading workflow each one was tested in, and ask for the dated release behind any claim you are shown. Hologic also states on its own breast health AI page that Quantra 2.2 breast density software is manufactured by Therapixel and distributed by Hologic, with clearance K240301, which is one of the records filed under the Therapixel applicant name. Confirmed 2026-10-10.

No ownership change was found. Checked on 2026-10-10 against the company's own site, which still presents Therapixel as an independent French software company working on medical imaging.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

No dated update is in the editorial file yet. Use the verified company sources below and check the profile verification date before relying on an older announcement.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The careers page describes the kind of person the company wants rather than naming teams or job titles, and invites applications even when nothing is posted.

Qualification signal: Breast screening is one of the most studied uses of imaging AI, so reader study design, clinical validation and 510(k) submission work count for more here than general computer vision experience.

Check current roles at Therapixel. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

Therapixel appears on 5 cleared products in the federal 510(k) record, across 1 device type.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources